BAYER "DEAR DOCTOR" LETTER PUBLIC AIRING OBVIATES CORRECTIVE ACTION, FDA SAYS; DDMAC DISSUADES HMR FROM USING REPRINT COMPARING CARDIZEM CD AND DILACOR XR
Executive Summary
Bayer will not be required to take corrective action concerning its distribution of a letter to physicians intended to counter recent negative publicity concerning calcium channel blockers, FDA's Division of Drug Marketing, Advertising & Communications told the company.